Market capitalization | $66.93m |
Enterprise Value | $-1.05m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.01 |
P/B ratio (TTM) P/B ratio | 0.33 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-72.95m |
Free cash flow (TTM) Free cash flow | $-73.96m |
Cash position | $153.79m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
3 Analysts have issued a Instil Bio Inc forecast:
3 Analysts have issued a Instil Bio Inc forecast:
Mar '24 | |
Current assets | 161 161 |
Fixed assets | 145 145 |
Total assets | 306 306 |
Mar '24 | |
Equity | 206 206 |
Debt capital | 100 100 |
Total capital | 306 306 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.
Head office | United States |
CEO | Bronson Crouch |
Employees | 49 |
Founded | 2018 |
Website | www.instilbio.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.